Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?

Core Viewpoint - Harrow (HROW) shares experienced a significant increase of 9.7% to $44.9, following the company's reaffirmation of its revenue guidance for full-year 2025 and ongoing progress in its commercial and development initiatives [1][2]. Group 1: Company Performance - Harrow plans to double its VEVYE sales team, expand IHEEZO into office-based care, and double the surgical sales force for TRIESENCE [2]. - The company is expected to report quarterly earnings of $0.35 per share, reflecting a year-over-year increase of 40%, with revenues projected at $87.5 million, up 30.9% from the same quarter last year [3]. - The consensus EPS estimate for Harrow has been revised 117.4% higher over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. Group 2: Industry Context - Harrow operates within the Zacks Medical - Drugs industry, where another company, Assertio (ASRT), saw a 3.9% increase in its stock price, closing at $12.24, and has returned 28.9% over the past month [5]. - Assertio's consensus EPS estimate has decreased by 1.4% over the past month to -$3.05, representing a significant decline of 84.9% compared to the previous year [6].